
    
      This study is a Phase II multi-site, randomized, double-blind placebo controlled trial to
      determine safety, feasibility, and efficacy of senolytics in older adults with amnestic mild
      cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who
      are tau PET positive.
    
  